Earlier this year, the United Kingdom (UK) reached a landmark in public health history. In April, Royal Assent was granted to the Tobacco and Vapes Act 2026, enshrining in law a generational ban on selling tobacco products to anyone born on or after January 1, 2009. Beginning on January 1, 2027, it will be illegal to sell tobacco to this cohort, a prohibition that will apply for the remainder of their lives. The UK becomes the first major economy to enact such legislation nationally, following the Maldives’ pioneering generational ban implemented in November 2025.1

For the lung cancer community, this is a moment of historic significance. Smoking remains responsible for more than 80% of lung cancer cases globally.2 The Act represents a structural commitment to ending the tobacco epidemic rather than managing it alone, a paradigm shift from the incremental demand-reduction strategies that have defined tobacco control for six decades. Reducing the number of people who ever start smoking is the most effective way to reduce lung cancer rates in the future. Combined with provisions to restrict the accessibility and appeal of nicotine vapes to young people and individuals who never smoked, whilst supporting their role as an effective tobacco cessation tool3 and extending smoke-free and vape-free environments,¹⁰ the act is among the most comprehensive tobacco control legislation enacted anywhere in the world.
And yet, for those working with the communities most devastated by tobacco, this moment demands careful, clear-eyed scrutiny. Legislation is not a guarantee of equity. Without a deliberate and well-resourced focus on tobacco cessation strategies that confront the entrenched social determinants of tobacco dependence, there is a genuine risk that the act accelerates a tobacco endgame for some, while leaving others behind.
The Hidden Emergency
National smoking prevalence in the UK has fallen to close to 10%, but this success masks a profoundly unequal distribution of harm. Smoking is now heavily concentrated in communities already shaped by poverty, structural disadvantage, and chronic social marginalization. A recent report from the Royal College of Physicians makes clear that the effects of smoking are increasingly borne by people living in deprivation, poor health, and social exclusion.4 Smoking prevalence in the most deprived areas of England can exceed 25% to 30%, while in the most affluent communities it falls below 5%.4 Among people living with serious mental illness, prevalence exceeds 50%.4
Tobacco dependence in these populations is not a matter of individual choice. It is a chronic, relapsing condition shaped by addiction, trauma, targeted commercial practices, and profoundly unequal access to evidence-based cessation support.4 The tobacco industry has historically directed its marketing with precision toward communities experiencing hardship and continues to do so globally.5
The Act’s generational sales restriction is rightly celebrated. But its primary mechanism, preventing future uptake, will not reach the millions of people in the UK who smoke today, concentrated in the communities that can least afford the health consequences. Endgame policy focused on reducing uptake, however bold, must be matched with equally bold investment in endgame policy focused on cessation treatment.
The Equity Imperative

The Royal College of Physicians’ report makes a compelling case that opt-out tobacco dependency treatment, with proactive, systematic cessation support embedded across all National Health System clinical settings, is a moral and clinical imperative.4 Emergency departments, inpatient wards, outpatient clinics, mental health services, maternity care, and community settings all represent an opportunity to offer evidence-based treatment to people who may not seek help otherwise.
This approach is not new. The Ottawa Model of Smoking Cessation has provided the evidence base for opt-out cessation systems in healthcare settings for more than two decades, and its principles have been implemented at scale across the NHS in England with a national program of hospital-based tobacco dependency treatment pathways for inpatients.6,7 The clinical and health economic evidence is robust: systematic, proactive cessation intervention in healthcare settings is both clinically effective and highly cost-effective, and this is especially true within lung cancer screening.8,9
Without sufficient investment in these treatment pathways, the Tobacco and Vapes Act risks becoming the endgame for the affluent, while tobacco harm entrenches further in the communities already carrying the greatest burden of cancer, cardiovascular disease and chronic respiratory illness. Our approach to smoking cessation moving forward must be one of ‘proportionate universalism’. Whilst services should be universal, they should be delivered with a depth and intensity that matches the level of need, effectively weighted towards those people carrying the heaviest burden.
The Lesson from New Zealand
The international community must also take seriously the warning from New Zealand, whose world-leading Smokefree legislation, widely regarded as among the most ambitious endgame strategies globally, was repealed following a change of government before full implementation could occur.10 That reversal demonstrated with painful clarity how vulnerable long-term public health policy can be to political discontinuity. The UK act enjoys broad cross-party support and is designed to avoid the most politically contentious elements that contributed to New Zealand’s reversal. Nevertheless, sustained professional advocacy, public education, and clinical engagement remain essential to protect its implementation and build the treatment infrastructure it demands.
A Call to Action
For the lung cancer community, the Tobacco and Vapes Act 2026 is not a signal to step back; it is a call to step forward. Smoking is the most important modifiable risk factor for lung cancer. Its eradication is our most powerful prevention strategy. The act creates the legislative architecture for a future tobacco endgame; the clinical community must now build clinical pathways embedded in all aspects of lung cancer care, from screening to diagnosis to treatment. That means advocating for opt-out cessation treatment as a standard of care across all healthcare settings. It means directing research and clinical innovation toward the populations that carry the greatest tobacco burden. It means recognizing that tobacco dependence is a health inequality and treating it with the same urgency we bring to any other driver of preventable cancer mortality.
The UK has taken a historic step towards a tobacco endgame. Delivering its full impact now requires rapid, large-scale action to ensure no one is left behind.
References
- 1. Tobacco and Vapes Act 2026. UK Parliament. Royal Assent 29 April 2026. Available at: bills.parliament.uk/bills/3879
- 2. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263.
- 3. Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews. 2024. doi: 10.1002/14651858.CD010216.pub9
- 4. Royal College of Physicians. Smoking, Health and Social Justice. London: RCP; 2021. Available at: rcp.ac.uk/policy-and-campaigns/policy-documents/smoking-health-and-social-justice
- 5. Faseru B, Dresler C. Tobacco endgame: a critical frontier for lung cancer prevention and equity. ILCN. April 2026. Available at: ilcn.org/tobacco-endgame-a-critical-frontier-for-lung-cancer-prevention-and-equity
- 6. Mullen KA, Manuel DG, Hawken SJ, et al. Effectiveness of a hospital-initiated smoking cessation programme: 2-year health and healthcare outcomes. Tobacco Control 2017;26:293–299.
- 7. Agrawal S, Cilia La Corte P, Frost T, et al. Is the provision of a national opt-out tobacco dependence treatment service in acute hospitals in England equitable? A national cohort study. Thorax 2026;81:156–163.
- 8. Evison M, Naylor R, Malcolm R, et al. Health economic model to evaluate the cost-effectiveness of smoking cessation services integrated within lung cancer screening in the United Kingdom. Thorax. Published Online First: 06 January 2026. doi: 10.1136/thorax-2024-222815
- 9. Williams PJ, Philip KE, Alghamdi SM, Perkins AM, Buttery SC, Polkey MI, Laverty AA, Hopkinson NS. Strategies to deliver smoking cessation interventions during targeted lung health screening — a systematic review and meta-analysis. Chron Respir Dis. 2023 Jan-Dec;20:14799731231183446.
- 10. New Zealand Ministry of Health. Smokefree Aotearoa 2025 Action Plan [repealed 2023]. Wellington: MoH; 2021.
